Gordon, Jessica K.

Publications

Sort by

Co-Author Network

selected publications

A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. Rheumatology (Oxford, England). 2022 Review GET IT
Times cited: 3
Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. ACR open rheumatology. 2022 Academic Article GET IT
Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. ACR open rheumatology. 2022 Academic Article GET IT
Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry. Rheumatology (Oxford, England). 2022 Academic Article GET IT
Times cited: 2
Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and feasibility studies. 2022 Academic Article GET IT
Times cited: 2
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study. The Lancet. Rheumatology. 2022 Academic Article GET IT
Times cited: 7
Magnetic Resonance Angiography of the Hand Vasculature in Patients With Systemic Sclerosis and Systemic Lupus Erythematosus. Hand (New York, N.Y.). 2021 Academic Article GET IT
Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. International journal of rheumatic diseases. 2021 Academic Article GET IT
The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials. 2021 Academic Article GET IT
Times cited: 3
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best practice & research. Clinical rheumatology. 2021 Review GET IT
Times cited: 14
Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis research & therapy. 2021 Academic Article GET IT
Times cited: 19
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. Arthritis & rheumatology (Hoboken, N.J.). 2021 Academic Article GET IT
Times cited: 13
Thirty-day hospital readmission in systemic sclerosis associated pulmonary hypertension: A nationwide study. Seminars in arthritis and rheumatism. 2021 Academic Article GET IT
Times cited: 3
Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker. Current rheumatology reports. 2020 Review GET IT
Times cited: 1
Response to: 'Correspondence on 'Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement'' by Manetti. Annals of the rheumatic diseases. 2020 Comment GET IT
Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. Clinical rheumatology. 2020 Academic Article GET IT
Times cited: 6
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. The Lancet. Rheumatology. 2020 Academic Article GET IT
Times cited: 21
Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. Annals of the rheumatic diseases. 2020 Academic Article GET IT
Times cited: 12
Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.). 2020 Academic Article GET IT
Times cited: 28
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.). 2020 Academic Article GET IT
Times cited: 58
Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Seminars in arthritis and rheumatism. 2020 Academic Article GET IT
Times cited: 14
Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma. Journal of scleroderma and related disorders. 2020 Review GET IT
Times cited: 3
The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR research protocols. 2020 Academic Article GET IT
Times cited: 5
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 38
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.). 2019 Academic Article GET IT
Times cited: 127
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Annals of the rheumatic diseases. 2019 Academic Article GET IT
Times cited: 68
Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. Clinical rheumatology. 2019 Academic Article GET IT
Times cited: 10
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis research & therapy. 2019 Academic Article GET IT
Times cited: 18
Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. The Journal of rheumatology. 2019 Academic Article GET IT
Times cited: 10
Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clinical and experimental rheumatology. 2018 Academic Article GET IT
Times cited: 27
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford, England). 2018 Academic Article GET IT
Times cited: 36
Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. Arthritis & rheumatology (Hoboken, N.J.). 2018 Academic Article GET IT
Times cited: 8
An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. Journal of scleroderma and related disorders. 2018 Academic Article GET IT
Times cited: 44
Inflammatory arthritis in systemic sclerosis: What to do?. Journal of scleroderma and related disorders. 2018 Review GET IT
Times cited: 5
Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. Journal of scleroderma and related disorders. 2018 Academic Article GET IT
Times cited: 30
Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Science translational medicine. 2018 Academic Article GET IT
Times cited: 124
Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort. Pulmonary circulation. 2018 Academic Article GET IT
Times cited: 11
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis & rheumatology (Hoboken, N.J.). 2017 Academic Article GET IT
Times cited: 78
Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. Medicine. 2017 Academic Article GET IT
Times cited: 60
Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. The Journal of investigative dermatology. 2017 Academic Article GET IT
Times cited: 39
Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort. Respirology (Carlton, Vic.). 2017 Academic Article GET IT
Times cited: 7
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment. The Journal of rheumatology. 2017 Academic Article GET IT
Times cited: 17
Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. The Journal of rheumatology. 2017 Academic Article GET IT
Times cited: 13
Integration of capillary microscopy and dermoscopy into the rheumatology fellow curriculum. Clinical and experimental rheumatology. 2017 Academic Article GET IT
Times cited: 6
Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. JCI insight. 2016 Academic Article GET IT
Times cited: 387
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical and experimental rheumatology. 2016 Academic Article GET IT
Times cited: 14
Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension. Rheumatology (Oxford, England). 2016 Academic Article GET IT
Times cited: 3
Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 36
A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin. The Journal of investigative dermatology. 2016 Academic Article GET IT
Times cited: 25
Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2016 Academic Article GET IT
Times cited: 707
Clinical Trial Design Issues in Systemic Sclerosis: an Update. Current rheumatology reports. 2016 Review GET IT
Times cited: 12
African American race associated with body image dissatisfaction among patients with systemic sclerosis. Clinical and experimental rheumatology. 2016 Academic Article GET IT
Times cited: 8
Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis. Arthritis research & therapy. 2016 Academic Article GET IT
Times cited: 14
A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis & rheumatology (Hoboken, N.J.). 2015 Academic Article GET IT
Times cited: 81
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis research & therapy. 2015 Academic Article GET IT
Times cited: 63
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 241
Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Seminars in arthritis and rheumatism. 2015 Academic Article GET IT
Times cited: 17
SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN. The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society. 2015 Academic Article GET IT
Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. 2015 GET IT
Times cited: 6
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clinical and experimental rheumatology. 2014 Academic Article GET IT
Times cited: 24
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis care & research. 2014 Academic Article GET IT
Times cited: 122
SSc management--In person appointments and remote therapy (SMART): a framework for management of chronic hand conditions. Journal of hand therapy : official journal of the American Society of Hand Therapists. 2013 Review GET IT
Times cited: 7
Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology (Oxford, England). 2013 Review GET IT
Times cited: 71
Submaximal heart and pulmonary evaluation: a novel noninvasive test to identify pulmonary hypertension in patients with systemic sclerosis. Arthritis care & research. 2013 Academic Article GET IT
Times cited: 5
Treatment of early diffuse systemic sclerosis skin disease. Clinical and experimental rheumatology. 2013 Review GET IT
Times cited: 38
Low prevalence of coeliac disease in patients with systemic sclerosis: a cross-sectional study of a registry cohort. Rheumatology (Oxford, England). 2013 Academic Article GET IT
Times cited: 17
Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies. International journal of rheumatology. 2011 Academic Article GET IT
Times cited: 6
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Annals of the rheumatic diseases. 2011 Academic Article GET IT
Times cited: 152
Imatinib and the treatment of fibrosis: recent trials and tribulations. Current rheumatology reports. 2011 Review GET IT
Times cited: 24
Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Current opinion in rheumatology. 2010 Review GET IT
Times cited: 20
Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). 2009 GET IT
Times cited: 24
Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2009 Conference Paper GET IT
Times cited: 203

more ...

less ...

Background

education and training

M.D., State University of New York at Stony Brook 2002
B.A., Brown University 1997

Contact

full name

Jessica K. Gordon

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Jessica K. Gordon Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

webpage